Translational Lung Cancer Research

Article	Citations
Radiomics and artificial intelligence in lung cancer screening	83
A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications	71
Targeting ferroptosis for cancer therapy: exploring novel strategies from its mechanisms and role in cancers	69
A narrative review of digital pathology and artificial intelligence: focusing on lung cancer	60
New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts	56
Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival	54
Patient-derived cell line, xenograft and organoid models in lung cancer therapy	53
Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer	51
Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET/CT radiomic features	50
PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy	49
Tumor-associated macrophages secret exosomal miR-155 and miR-196a-5p to promote metastasis of non-small-cell lung cancer	47
Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma	43
Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients	43
Clinical significance of histologic subtyping of malignant pleural mesothelioma	41
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer	41
Current progress and mechanisms of bone metastasis in lung cancer: a narrative review	37
Emerging and multifaceted role of neutrophils in lung cancer	36
Transbronchial microwave ablation of lung nodules with electromagnetic navigation bronchoscopy guidance—a novel technique and initial experience with 30 cases	36
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab	35
Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: ready for practice?	35
Microbiota dysbiosis in lung cancer: evidence of association and potential mechanisms	34
Lung cancer screening and smoking cessation efforts	34
The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility	33
Preoperative peripheral blood neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratio (PLR) related nomograms predict the survival of patients with limited-stage small-cell lung cancer	33
Predicting the invasiveness of lung adenocarcinomas appearing as ground-glass nodule on CT scan using multi-task learning and deep radiomics	32

Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study	32
Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis	31
Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review	31
Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1	31
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples	31
Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis	30
3D radiomics predicts EGFR mutation, exon-19 deletion and exon-21 L858R mutation in lung adenocarcinoma	30
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutati	29
Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program	29
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups	28
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations	28
Prognostic value of log odds of positive lymph nodes in node-positive lung squamous cell carcinoma patients after surgery: a SEER population-based study	27
KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma	27
Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors	27
Artificial intelligence and lung cancer treatment decision: agreement with recommendation of multidisciplinary tumor board	27
Lung cancer screening in Europe: where are we in 2021?	27
Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2	26
Circulating tumor cells can predict the prognosis of patients with non-small cell lung cancer after resection: a retrospective study	26
Expert consensus on resection of chest wall tumors and chest wall reconstruction	26
Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study	25
Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer	25
tsRNA-5001a promotes proliferation of lung adenocarcinoma cells and is associated with postoperative recurrence in lung adenocarcinoma patients	25
Radiomics nomogram for prediction disease-free survival and adjuvant chemotherapy benefits in patients with resected stage I lung adenocarcinoma	25
The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis	25
Exploration of radiation-induced lung injury, from mechanism to treatment: a narrative review	24
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung c	24
Significance of tumor spread through air spaces (STAS) in lung cancer from the pathologist perspective	24
Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas	23
circFBXW7 attenuates malignant progression in lung adenocarcinoma by sponging miR-942-5p	23
Molecular biomarkers in early stage lung cancer	23
Lung cancer biomarker testing: perspective from Europe	23
Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy	23
Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer	23
A review on the impact of lung cancer multidisciplinary care on patient outcomes	22
Controversies and challenges in the histologic subtyping of lung adenocarcinoma	22
Deubiquitinase USP5 promotes non-small cell lung cancer cell proliferation by stabilizing cyclin D1	22
High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)	22
A signature of estimate-stromal-immune score-based genes associated with the prognosis of lung adenocarcinoma	21
Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab	21
Radiotherapy programs neutrophils to an antitumor phenotype by inducing mesenchymal-epithelial transition	21
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis	21
Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study	21
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis	21
Circ-AASDH functions as the progression of early stage lung adenocarcinoma by targeting miR-140-3p to activate E2F7 expression	21
Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study	20
CircP4HB regulates ferroptosis via SLC7A11-mediated glutathione synthesis in lung adenocarcinoma	20
Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis	20
PD-L1 as a prognostic biomarker in surgically resectable non- small cell lung cancer: a meta-analysis	20
A machine learning-based prediction of the micropapillary/solid growth pattern in invasive lung adenocarcinoma with radiomics	20
Latest CT technologies in lung cancer screening: protocols and radiation dose reduction	20

Feasibility of implementing a national lung cancer screening program: Interim results from the Korean Lung Cancer Screening Project (K-LUCAS)	19
Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy	19
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer	19
Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure	19
B cells in lung cancer—not just a bystander cell: a literature review	19
Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors	19
Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer	19
MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer	19
cGAS-STING pathway expression as a prognostic tool in NSCLC	19
Implementation of lung cancer screening: what are the main issues?	19
PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer	19
Let-7b-3p inhibits tumor growth and metastasis by targeting the BRF2-mediated MAPK/ERK pathway in human lung adenocarcinoma	18
Decade in review: a new era for RET-rearranged lung cancers	18
Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)	18
Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with	18
Arsenic trioxide inhibits the growth of cancer stem cells derived from small cell lung cancer by downregulating stem cell- maintenance factors and inducing apoptosis via the Hedgehog signaling blockad	18
18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiomic features for prediction of epidermal growth factor receptor mutation status and prognosis in patients with lung a	18
Added benefits of early detection of other diseases on low-dose CT screening	17
Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series	17
Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer	17
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations	17
Multidisciplinary team care in advanced lung cancer	17
Prognostic implications of cellular senescence in resected non-small cell lung cancer	17
A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients	17
A nomogram for predicting the risk of lymph node metastasis in T1–2 non-small-cell lung cancer based on PET/CT and clinical characteristics	17
18F-RGD PET/CT imaging reveals characteristics of angiogenesis in non-small cell lung cancer	17
Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study	17
Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study	17
Uniportal video-assisted thoracic surgery for the treatment of lung cancer: a consensus report from Chinese Society for Thoracic and Cardiovascular Surgery (CSTCVS) and Chinese Association of Thoracic	17
LINC00511 promotes lung squamous cell carcinoma proliferation and migration via inhibiting miR-150-5p and activating TADA1	17
Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis	16
SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer	16
EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study	16
A pilot study of the ultrathin cryoprobe in the diagnosis of peripheral pulmonary ground-glass opacity lesions	16
Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer	16
Impact of time-to-treatment on overall survival of non-small cell lung cancer patients—an analysis of the national cancer database	16
Immunocytochemistry of cytology specimens for predictive biomarkers in lung cancer	16
Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer	16
Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer	16
M5C regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in lung adenocarcinoma	16
Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review	16
Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors	16
Participation in lung cancer screening	16
Association between dietary sodium, potassium intake and lung cancer risk: evidence from the prostate, lung, colorectal and ovarian cancer screening trial and the Women’s Health Initiative	16
Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy	15
Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk	15
Low-level expression of necroptosis factors indicates a poor prognosis of the squamous cell carcinoma subtype of non-small-cell lung cancer	15
Can autoantibody tests enhance lung cancer screening?—an evaluation of EarlyCDT®-Lung in context of the German Lung Cancer Screening Intervention Trial (LUSI)	15
Role of lymphatic endothelial cells in the tumor microenvironment—a narrative review of recent advances	15
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)	15
Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review	15
Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy—case report	15
Mediastinal staging for non-small cell lung cancer	15
Comparison between closed pleural biopsy and medical thoracoscopy for the diagnosis of undiagnosed exudative pleural effusions: a systematic review and meta-analysis	15
The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer	15
Three-dimensional reconstruction/personalized three-dimensional printed model for thoracoscopic anatomical partial-lobectomy in stage I lung cancer: a retrospective study	15
Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab	15
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib	15
Genetic and microenvironmental differences in non-smoking lung adenocarcinoma patients compared with smoking patients	14
Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo	14
Primary tumor and metastasis—sectioning the different steps of the metastatic cascade	14
Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer	14
A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer	14
CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer	14
Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance	14
Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients	14
Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review	14
Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system	14
Accuracy of lung cancer staging in the multidisciplinary team setting	14
Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer	14
Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)	14
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer	14
Pulmonary function changes after thoracoscopic lobectomy versus intentional thoracoscopic segmentectomy for early-stage non-small cell lung cancer	14
Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma	14
COVID-19 and early-stage lung cancer both featuring ground-glass opacities: a propensity score-matched study	14
High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations	13
Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists	13
The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients	13
ACOT11 promotes cell proliferation, migration and invasion in lung adenocarcinoma	13
Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma	13

Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative	13
Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents	13
Immunotherapy beyond progression in patients with advanced non-small cell lung cancer	13
Identifying optimal candidates for primary tumor resection among metastatic non-small cell lung cancer patients: a population-based predictive model	13
Dose and fractionation schedules in radiotherapy for non-small cell lung cancer	13
Predicting brain metastasis in early stage non-small cell lung cancer patients by gene expression profiling	13
Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR	13
One carbon metabolism in human lung cancer	13
Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma	13
Thoracic radiotherapy in small cell lung cancer—a narrative review	13
Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments	13
The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy	13
The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review	13
Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States	13
Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer	12
Prediction of future imagery of lung nodule as growth modeling with follow-up computed tomography scans using deep learning: a retrospective cohort study	12
Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report	12
Earlier extracranial progression and shorter survival in ALK- rearranged lung cancer with positive liquid rebiopsies	12
TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy—EGFR mutated non-small cell lung cancer IV patients treated with osimertinib	12
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won	12
Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells	12
Inhaled corticosteroids and risk of lung cancer among chronic obstructive pulmonary disease patients: a comprehensive analysis of nine prospective cohorts	12
Triptolide inhibits epithelial-mesenchymal transition phenotype through the p70S6k/GSK3/β-catenin signaling pathway in taxol-resistant human lung adenocarcinoma	12
Genomic profiling of extracellular vesicle-derived DNA from bronchoalveolar lavage fluid of patients with lung adenocarcinoma	12
A prognostic nomogram for lung adenocarcinoma based on immune-infiltrating Treg-related genes: from bench to bedside	12
High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer	12
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report	12
Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy	11
Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer	11
Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer	11
The effect of combining Endostar with radiotherapy on blood vessels, tumor-associated macrophages, and T cells in brain metastases of Lewis lung cancer	11
BCKDK alters the metabolism of non-small cell lung cancer	11
Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma	11
CD39: the potential target in small cell lung cancer	11
PRRX1 isoform PRRX1A regulates the stemness phenotype and epithelial-mesenchymal transition (EMT) of cancer stem-like cells (CSCs) derived from non-small cell lung cancer (NSCLC)	11
EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients	11
A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma	11
Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study	11
The effectiveness of three-dimensional reconstruction in the localization of multiple nodules in lung specimens: a prospective cohort study	11
Immunotherapy in malignant pleural mesothelioma: a review of literature data	11
The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review	11
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma	11
Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer	11
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer	11
Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy	11
Increased detection of circulating tumor DNA by short fragment enrichment	11
Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study	11
Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience	11
Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review	11
Role of the epithelial-mesenchymal transition-related circular RNA, circ-10720, in non-small-cell lung cancer	11
Ongoing challenges in implementation of lung cancer screening	11
Comparison of perioperative outcomes of robotic-assisted versus video-assisted thoracoscopic right upper lobectomy in non-small cell lung cancer	11
Preoperative computer tomography-guided indocyanine green injection is associated with successful localization of small pulmonary nodules	11
Challenges in the target volume definition of lung cancer radiotherapy	11
Electromagnetic bronchoscopy guided microwave ablation for early stage lung cancer presenting as ground glass nodule	11
Hsa_circ_0006571 promotes spinal metastasis through sponging microRNA-138 to regulate sirtuin 1 expression in lung adenocarcinoma	11
The protective effects of granulocyte-macrophage colony-stimulating factor against radiation-induced lung injury	11
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies	11
Application of indocyanine green injection guided by electromagnetic navigation bronchoscopy in localization of pulmonary nodules	11
A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future	11
Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse	11
Lung cancer screening: targeting the hard to reach—a review	11
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer	11
Role of radiomics in predicting lung cancer spread through air spaces in a heterogeneous dataset	10
Managing of screening-detected sub-solid nodules—a European perspective	10
Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer	10
International expert consensus on immunotherapy for early-stage non-small cell lung cancer	10
Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance	10
Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib	10
The person behind the nodule: a narrative review of the psychological impact of lung cancer screening	10
Assessing the association of diabetes with lung cancer risk	10
Public opinion on implementing the National Lung Cancer Screening Program in Korea	10
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?	10
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy	10
Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib	10
Earlier multidisciplinary palliative care intervention for people with lung cancer: a systematic review and meta-analysis	10
Does size matter? —a population-based analysis of malignant pleural mesothelioma	10
NLRP3 activation in tumor-associated macrophages enhances lung metastasis of pancreatic ductal adenocarcinoma	10
Clinical features and prognostic factors of combined small cell lung cancer: development and validation of a nomogram based on the SEER database	10
Should resection extent be decided by total lesion size or solid component size in ground glass opacity-containing lung adenocarcinomas?	10
Cancer-associated changes of emotional brain network in non-nervous system metastatic non-small cell lung cancer patients: a structural connectomic diffusion tensor imaging study	10
A uniportal right upper lobectomy by three-arm robotic-assisted thoracoscopic surgery using the da Vinci (Xi) Surgical System in the treatment of early-stage lung cancer	10
International consensus on radiotherapy in metastatic non-small cell lung cancer	10
Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study	10
Robotic-assisted thoracic surgery reduces perioperative complications and achieves a similar long-term survival profile as posterolateral thoracotomy in clinical N2 stage non-small cell lung cancer pa	10
Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach	10
Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in locally advanced non-small cell lung cancer: a case report	10
Causal effects of genetically determined metabolites on cancers included lung, breast, ovarian cancer, and glioma: a Mendelian randomization study	10
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done	10
TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular signal-regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	10
New insights into the interaction of the immune system with non-small cell lung carcinomas	10
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study	10
A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real w	10
Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with defini	10
Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients wit	9